Zai Lab sees profits on the horizon as commercialization accelerates
The innovative drug maker’s loss narrowed last year, as it forecast potential profitability as soon as 2025 on fast-growing revenues Key Takeaways: Zai Lab is set to reach several product…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
